Option Chain

C4 Therapeutics Inc

CCCCNASDAQ · USD

3.10USD+0.15 (+5.09%)

259

C4 Therapeutics Inc (CCCC) Option Chain

Tracking the CCCC option chain helps you see every strike and expiry on C4 Therapeutics Inc in one view, so you can quickly identify contracts that fit your thesis and your risk. It lays out bids, asks, volume, open interest, and Greeks across calls and puts, giving you the full map of CCCC options activity at a glance. Use our scanner to monitor the CCCC option chain in real time and filter for the trades that actually meet your criteria.

An option chain is the complete listing of all available option contracts on an underlying, organized by expiration date and strike price. For CCCC stock options, the chain shows call and put data side by side, making it easy to compare premiums, assess liquidity, and spot pricing dislocations. Reading it well means looking beyond the last price. Implied volatility by strike, volume to open interest ratios, and bid ask spreads all show where CCCC options are being actively traded, and where they are not.

C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma. The company is also developing CFT8634, an orally bioavailable BiDAC degrader of BRD9, a protein target for synovial sarcoma and SMARCB1-deleted solid tumors; CFT1946, an orally bioavailable BiDAC degrader targeting V600X mutant BRAF to treat melanoma, non-small cell lung cancer (NSCLC), colorectal cancer, and other solid malignancies; CFT8919, an orally bioavailable, allosteric, and mutant-selective BiDAC degrader of epidermal growth factor receptor, or EGFR, with an L858R mutation in NSCLC; and earlier stage programs comprising RET degraders for the treatment of various cancers.

CALLs									PUTs
Prob. OTM %	Open Interest	Volume	Extrinsic Value	Intrinsic Value	Bid	Ask	Strike	Moneyness %	Bid	Ask	Intrinsic Value	Extrinsic Value	Volume	Open Interest	Prob. OTM %
0.00	0	0	-0.15	2.10	1.45	2.45	1.00	-66.10	—	0.05	0.00	0.05	0	0	100.00
9.19	20	0	-0.05	1.10	0.55	1.55	2.00	-32.20	—	0.10	0.00	0.10	0	188	90.81
57.55	224	3	0.30	0.10	0.15	0.65	3.00	+1.69	—	0.55	0.00	0.55	3	441	42.45
89.77	233	0	0.25	0.00	—	0.25	4.00	+35.59	0.60	1.60	0.90	0.20	0	20	10.23
98.23	3	0	0.40	0.00	—	0.40	5.00	+69.49	1.65	2.60	1.90	0.23	0	0	1.77

As of Nov 5, 2026

Prices move. This one stays.Lock in 5 years at a special price and save $2,243. Ending soon.See the Early Bird Black Friday deal →

Stock Statistics

IndustryBiotechnology
SectorHealthcare
IV Rank62.30% Moderate
Market cap (M$)363
52 weeks high-42.94%
52 weeks low74.56%
Analyst recommendationStrong Buy
1.11
Target price$12.50
307.10% above the current stock price
Dividend—
Payout ratio—
Earnings date2026-11-05
P/E—
Future P/E—
EPS (ttm)-1.00
EPS growth next 5 years5.85%

As of Nov 5, 2026

Browse all Option Chain tickers